Alder Biopharmaceuticals, Inc. (ALDR) Analysts See $-1.26 EPS; Broadview Advisors Lifted Parsley Energy (PE) Position By $4.10 Million

April 17, 2018 - By mmahotstuff

Broadview Advisors Llc increased Parsley Energy Inc (PE) stake by 209.53% reported in 2017Q4 SEC filing. Broadview Advisors Llc acquired 141,325 shares as Parsley Energy Inc (PE)’s stock declined 8.80%. The Broadview Advisors Llc holds 208,775 shares with $6.15M value, up from 67,450 last quarter. Parsley Energy Inc now has $9.26B valuation. The stock increased 0.24% or $0.07 during the last trading session, reaching $29.38. About 2.68M shares traded. Parsley Energy, Inc. (NYSE:PE) has declined 12.13% since April 17, 2017 and is downtrending. It has underperformed by 23.68% the S&P500.

Analysts expect Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) to report $-1.26 EPS on April, 26.They anticipate $0.73 EPS change or 36.68% from last quarter’s $-1.99 EPS. After having $-0.80 EPS previously, Alder Biopharmaceuticals, Inc.’s analysts see 57.50% EPS growth. The stock decreased 1.02% or $0.15 during the last trading session, reaching $14.55. About 803,324 shares traded. Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) has declined 46.26% since April 17, 2017 and is downtrending. It has underperformed by 57.81% the S&P500.

Alder BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes therapeutic antibodies in the United States, Australia, and Ireland. The company has market cap of $987.14 million. The company's lead product candidate includes ALD403, an antibody, which is in Phase II clinical trial to target calcitonin gene-related peptide for the prevention of migraine. It currently has negative earnings. It also develops ALD1910, a genetically engineered monoclonal antibody that is in preclinical study for the treatment of migraine; and Clazakizumab, an antibody, which has been completed Phase IIb clinical trial that inhibits the pro-inflammatory cytokine interleukin-6 for the treatment of rheumatoid and psoriatic arthritis.

Among 16 analysts covering Alder Biopharmaceuticals (NASDAQ:ALDR), 14 have Buy rating, 1 Sell and 1 Hold. Therefore 88% are positive. Alder Biopharmaceuticals had 34 analyst reports since August 6, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, June 8 by Needham. The firm has “Buy” rating given on Thursday, June 29 by Aegis Capital. The firm earned “Hold” rating on Thursday, August 24 by Credit Suisse. The rating was maintained by Piper Jaffray on Tuesday, June 27 with “Buy”. The stock has “Buy” rating by Needham on Tuesday, June 27. On Thursday, April 21 the stock rating was reinitiated by Wells Fargo with “Outperform”. The rating was maintained by Canaccord Genuity with “Buy” on Tuesday, January 30. The rating was initiated by Piper Jaffray with “Overweight” on Monday, October 31. Credit Suisse maintained the stock with “Outperform” rating in Tuesday, March 29 report. The company was initiated on Wednesday, April 20 by Brean Capital.

Investors sentiment decreased to 1.01 in Q4 2017. Its down 0.12, from 1.13 in 2017Q3. It dropped, as 49 investors sold PE shares while 96 reduced holdings. 54 funds opened positions while 93 raised stakes. 251.44 million shares or 1.93% more from 246.67 million shares in 2017Q3 were reported. Lombard Odier Asset Mngmt (Usa) owns 297,359 shares. Macquarie Group Inc Ltd accumulated 329,734 shares. Wellington Mngmt Group Inc Llp stated it has 2.50 million shares. Caisse De Depot Et Placement Du Quebec accumulated 0% or 19,800 shares. Quantitative Systematic Strategies Ltd Liability Co invested in 19,850 shares. Cap World Investors reported 0.01% stake. Element Mgmt Ltd owns 507,246 shares. Utah Retirement owns 43,500 shares or 0.03% of their US portfolio. Fred Alger invested in 105,181 shares. State Of Wisconsin Inv Board owns 663,897 shares. Viking Global Investors Ltd Partnership has invested 3.28% in Parsley Energy, Inc. (NYSE:PE). Advisory Rech, a Illinois-based fund reported 469,170 shares. Susquehanna Grp Llp, a Pennsylvania-based fund reported 52,529 shares. 1492 Cap Management reported 15,714 shares or 0.36% of all its holdings. Swiss Bank & Trust has invested 0.03% in Parsley Energy, Inc. (NYSE:PE).

Among 37 analysts covering Parsley Energy Inc (NYSE:PE), 29 have Buy rating, 0 Sell and 8 Hold. Therefore 78% are positive. Parsley Energy Inc had 138 analyst reports since July 21, 2015 according to SRatingsIntel. Barclays Capital maintained it with “Overweight” rating and $30 target in Tuesday, August 8 report. The firm has “Buy” rating by Stifel Nicolaus given on Monday, January 29. The firm has “Hold” rating given on Tuesday, January 30 by Citigroup. On Monday, June 12 the stock rating was upgraded by Williams Capital Group to “Buy”. The stock has “Hold” rating by Williams Capital Group on Monday, August 29. Piper Jaffray maintained it with “Buy” rating and $34.0 target in Monday, October 23 report. The stock of Parsley Energy, Inc. (NYSE:PE) has “Overweight” rating given on Tuesday, March 13 by JP Morgan. Credit Suisse maintained Parsley Energy, Inc. (NYSE:PE) on Wednesday, March 2 with “Outperform” rating. RBC Capital Markets maintained Parsley Energy, Inc. (NYSE:PE) on Tuesday, January 17 with “Outperform” rating. RBC Capital Markets maintained the stock with “Buy” rating in Thursday, September 7 report.

Parsley Energy, Inc. (NYSE:PE) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>